
NYSE:GL
This summary was created by AI, based on 7 opinions in the last 12 months.
Globe Life Inc. (GL-N) has garnered significant attention from analysts, consistently being labeled a 'TOP PICK' by Michael O'Reilly from Stockchase Research. The company recently demonstrated impressive financial performance, reporting a 20% increase in net income and a sustaining growth rate in book value by 20% annually over the past two years. Globe Life's financial metrics underscore its attractiveness, trading at a reasonable multiple of earnings (around 10-12x) and maintaining robust returns on equity in the range of 20-22%. Meanwhile, the company is effectively deploying cash reserves to buy back shares and manage debt, which adds to its appeal as a steady investment. Analysts predict further upside potential, with price targets generally above current trading levels, reflecting a strong endorsement of Globe Life's future prospects despite yielding a modest dividend of 0.6-0.7%.
Globe Life Inc. is a American stock, trading under the symbol GL (previously GL-N on Stockchase) on the New York Stock Exchange (GL). It is usually referred to as NYSE:GL or GL
In the last year, 8 stock analysts issued a Buy, Sell, or Hold rating on GL (previously GL-N on Stockchase). 8 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is TOP PICK. Read the latest stock experts' ratings for Globe Life Inc..
Globe Life Inc. was recommended as a Top Pick by The Panic-Proof Portfolio (Stockchase Research) on 2026-08-13. Read the latest stock experts ratings for Globe Life Inc..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Globe Life Inc..
Globe Life Inc. is covered by Stockchase experts and is worth watching.
On 2026-08-17, Globe Life Inc. (GL) stock closed at a price of $179.41.
We again reiterate this insurance provider as a TOP PICK. Recently reported earnings showed a 20% increase in net income. It trades at 12x earnings, 2.3x book and supports a 20% ROE. We continue to recommend a stop at $165, looking to achieve $214 -- upside potential of 18%. Yield 0.6%
(Analysts’ price target is $195.57)